Jane Street’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-161,500
| Closed | -$6.5M | – | 11469 |
|
|
2026
Q1 | $6.5M | Sell |
161,500
-111,000
| -41% | -$2.39M | ﹤0.01% | 3122 |
|
|
2025
Q4 | $6.85M | Buy |
272,500
+64,000
| +31% | +$1.5M | ﹤0.01% | 2790 |
|
|
2025
Q3 | $4.72M | Sell |
208,500
-7,100
| -3% | -$166K | ﹤0.01% | 3505 |
|
|
2025
Q2 | $3.73M | Sell |
215,600
-113,500
| -34% | -$2.1M | ﹤0.01% | 3416 |
|
|
2025
Q1 | $7.2M | Buy |
329,100
+24,100
| +8% | +$666K | ﹤0.01% | 2407 |
|
|
2024
Q4 | $9.73M | Buy |
305,000
+31,600
| +12% | +$950K | ﹤0.01% | 1911 |
|
|
2024
Q3 | $7.88M | Sell |
273,400
-93,200
| -25% | -$3.45M | ﹤0.01% | 2188 |
|
|
2024
Q2 | $14.1M | Buy |
366,600
+253,100
| +223% | +$11.5M | ﹤0.01% | 1655 |
|
|
2024
Q1 | $6.67M | Sell |
113,500
-102,300
| -47% | -$6.52M | ﹤0.01% | 2245 |
|
|
2023
Q4 | $12.9M | Sell |
215,800
-70,700
| -25% | -$3.59M | ﹤0.01% | 1680 |
|
|
2023
Q3 | $10.9M | Buy |
286,500
+125,900
| +78% | +$5.53M | ﹤0.01% | 1686 |
|
|
2023
Q2 | $14.6M | Buy |
160,600
+11,500
| +8% | +$992K | ﹤0.01% | 1513 |
|
|
2023
Q1 | $9.83M | Buy |
149,100
+88,600
| +146% | +$5.11M | ﹤0.01% | 1653 |
|
|
2022
Q4 | $3.13M | Sell |
60,500
-60,200
| -50% | -$3.19M | ﹤0.01% | 3154 |
|
|
2022
Q3 | $8.24M | Sell |
120,700
-9,300
| -7% | -$550K | ﹤0.01% | 1910 |
|
|
2022
Q2 | $5.88M | Sell |
130,000
-12,600
| -9% | -$574K | ﹤0.01% | 2432 |
|
|
2022
Q1 | $7.25M | Buy |
142,600
+106,300
| +293% | +$4.69M | ﹤0.01% | 2450 |
|
|
2021
Q4 | $1.72M | Sell |
36,300
-798,000
| -96% | -$31.4M | ﹤0.01% | 4792 |
|
|
2021
Q3 | $27.5M | Buy |
834,300
+772,000
| +1,239% | +$43.4M | 0.01% | 919 |
|
|
2021
Q2 | $3.94M | Buy |
+62,300
| New | +$3.21M | ﹤0.01% | 3063 |
|
|
2021
Q1 | – | Sell |
-11,700
| Closed | -$669K | – | 9046 |
|
|
2020
Q4 | $669K | Sell |
11,700
-12,100
| -51% | -$512K | ﹤0.01% | 5304 |
|
|
2020
Q3 | $718K | Buy |
23,800
+6,500
| +38% | +$194K | ﹤0.01% | 4619 |
|
|
2020
Q2 | $565K | Buy |
+17,300
| New | +$556K | ﹤0.01% | 4890 |
|
Other funds holding APLS
Jane Street's APLS Position: Q1 2026 in Review
Jane Street sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 50,114 shares — an estimated $1.08M sold.
Jane Street first reported a position in APLS in Q2 2019 and held it in 26 quarters. The position peaked at $43.8M in Q2 2023. 324 funds tracked by Wall St. Rank hold APLS as of Q1 2026.
- Jane Street reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 50,114 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.08M.
- Jane Street first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 26 quarters.
- Jane Street's Apellis Pharmaceuticals position peaked at $43.8M in Q2 2023.
- 324 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.